| Primary |
| Product Used For Unknown Indication |
42.0% |
| Foetal Exposure During Pregnancy |
9.9% |
| Cholestasis Of Pregnancy |
4.9% |
| Generalized Itching |
4.9% |
| Crohn's Disease |
3.7% |
| Hepatic Function Abnormal |
3.7% |
| Alcoholic Liver Disease |
2.5% |
| Biliary Cirrhosis Primary |
2.5% |
| Biliary Tract Infection Viral |
2.5% |
| Cholangitis Sclerosing |
2.5% |
| Drug Use For Unknown Indication |
2.5% |
| Jaundice |
2.5% |
| Liver Disorder |
2.5% |
| Nutritional Supplementation |
2.5% |
| Prophylaxis Against Graft Versus Host Disease |
2.5% |
| Pruritus Generalized |
2.5% |
| Schizophrenia |
2.5% |
| Ascites |
1.2% |
| Atrial Fibrillation |
1.2% |
| Cardiac Valve Prosthesis User |
1.2% |
|
| Bile Duct Stone |
6.9% |
| Dyspnoea |
6.9% |
| Erythema Multiforme |
6.9% |
| Pneumonia |
6.9% |
| Rash |
6.9% |
| Suicidal Ideation |
6.9% |
| Vomiting |
6.9% |
| Weight Decreased |
6.9% |
| White Blood Cell Count Decreased |
6.9% |
| Blood Bilirubin Increased |
3.4% |
| Cholangitis Acute |
3.4% |
| Drug-induced Liver Injury |
3.4% |
| Eczema |
3.4% |
| Foetal Exposure During Pregnancy |
3.4% |
| Human Herpesvirus 6 Infection |
3.4% |
| Ileus |
3.4% |
| International Normalised Ratio Increased |
3.4% |
| Interstitial Lung Disease |
3.4% |
| Lymphocyte Stimulation Test Positive |
3.4% |
| Maternal Exposure During Pregnancy |
3.4% |
|
| Secondary |
| Prophylaxis |
25.8% |
| Maternal Exposure Timing Unspecified |
10.6% |
| Neuroblastoma |
7.6% |
| Myelodysplastic Syndrome |
6.1% |
| Cytomegalovirus Infection |
4.5% |
| Depression |
4.5% |
| Product Used For Unknown Indication |
4.5% |
| Acute Graft Versus Host Disease |
3.0% |
| Bone Marrow Conditioning Regimen |
3.0% |
| Cardiac Failure Chronic |
3.0% |
| Cholestasis |
3.0% |
| Graft Haemorrhage |
3.0% |
| Headache |
3.0% |
| Hypertension |
3.0% |
| Liver Transplant |
3.0% |
| Nausea |
3.0% |
| Prophylaxis Against Graft Versus Host Disease |
3.0% |
| Pyrexia |
3.0% |
| Anxiety |
1.5% |
| Aspergillus Infection |
1.5% |
|
| Physical Assault |
15.4% |
| Thrombotic Microangiopathy |
15.4% |
| Inappropriate Antidiuretic Hormone Secretion |
7.7% |
| Interstitial Lung Disease |
7.7% |
| Intestinal Ulcer |
7.7% |
| Pyrexia |
7.7% |
| Renal Impairment |
7.7% |
| Syndactyly |
7.7% |
| Vanishing Bile Duct Syndrome |
7.7% |
| Venoocclusive Disease |
7.7% |
| Venoocclusive Liver Disease |
7.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.1% |
| Prophylaxis |
16.0% |
| Infection Prophylaxis |
8.4% |
| Prophylaxis Against Graft Versus Host Disease |
6.8% |
| Bone Marrow Conditioning Regimen |
6.5% |
| Hiv Infection |
5.2% |
| Hypertension |
4.7% |
| Premedication |
4.3% |
| Rheumatoid Arthritis |
3.8% |
| Drug Use For Unknown Indication |
3.4% |
| Antifungal Prophylaxis |
2.9% |
| Hepatitis C |
2.4% |
| Chronic Hepatitis C |
2.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.2% |
| Constipation |
2.1% |
| Antibiotic Prophylaxis |
1.9% |
| Insomnia |
1.9% |
| Acute Myeloid Leukaemia |
1.9% |
| Antiviral Prophylaxis |
1.7% |
| Liver Disorder |
1.7% |
|
| Pyrexia |
14.8% |
| White Blood Cell Count Decreased |
8.3% |
| Ascites |
7.7% |
| Stomatitis |
7.1% |
| Venoocclusive Liver Disease |
5.9% |
| Vomiting |
5.9% |
| Liver Disorder |
5.3% |
| Myositis |
4.1% |
| Staphylococcal Sepsis |
4.1% |
| Cerebral Infarction |
3.6% |
| Renal Failure Acute |
3.6% |
| Septic Shock |
3.6% |
| Thrombocytopenia |
3.6% |
| Thrombotic Microangiopathy |
3.6% |
| Weight Decreased |
3.6% |
| Weight Increased |
3.6% |
| Headache |
3.0% |
| Interstitial Lung Disease |
3.0% |
| Nausea |
3.0% |
| Neutrophil Count Decreased |
3.0% |
|
| Interacting |
| Computerised Tomogram |
100.0% |
|
|
